Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Liabilities (2021 - 2025)

Senti Biosciences has reported Total Liabilities over the past 5 years, most recently at $45.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 3.08% year-over-year to $45.6 million; the TTM value through Dec 2025 reached $45.6 million, down 3.08%, while the annual FY2025 figure was $45.6 million, 3.08% down from the prior year.
  • Total Liabilities for Q4 2025 was $45.6 million at Senti Biosciences, up from $44.6 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $53.5 million in Q4 2022 and troughed at $349835.0 in Q1 2021.
  • A 5-year average of $38.4 million and a median of $45.3 million in 2025 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 3073.28% in 2022 and later decreased 14.55% in 2024.
  • Year by year, Total Liabilities stood at $36.3 million in 2021, then soared by 47.36% to $53.5 million in 2022, then dropped by 1.79% to $52.6 million in 2023, then fell by 10.43% to $47.1 million in 2024, then fell by 3.08% to $45.6 million in 2025.
  • Business Quant data shows Total Liabilities for SNTI at $45.6 million in Q4 2025, $44.6 million in Q3 2025, and $43.9 million in Q2 2025.